Pharmaceutical compositions using semi-solid delivery vehicle
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-009/58
A61K-047/30
출원번호
US-0409408
(2003-04-07)
발명자
/ 주소
Ng, Steven Y.
Shen, Hui-Rong
Heller, Jorge
출원인 / 주소
AP Pharma Inc.
대리인 / 주소
Seidman Stephanie L.
인용정보
피인용 횟수 :
12인용 특허 :
24
초록▼
A semi-solid delivery vehicle contains a polyorthoester and an excipient, and a semi-solid pharmaceutical composition contains an active agent and the delivery vehicle. The pharmaceutical composition may be a topical, syringable, or injectable formulation; and is suitable for local delivery of the a
A semi-solid delivery vehicle contains a polyorthoester and an excipient, and a semi-solid pharmaceutical composition contains an active agent and the delivery vehicle. The pharmaceutical composition may be a topical, syringable, or injectable formulation; and is suitable for local delivery of the active agent. Methods of treatment are also disclosed.
대표청구항▼
1. A pharmaceutical composition, comprising:(a) an active agent; and(b) a semi-solid delivery vehicle comprising:(i) a polyorthoester of formula I or formula II where:R is a bond, —(CH 2 ) a —, or —(CH 2 ) b —O—(CH 2 ) c —; where a is an integer
1. A pharmaceutical composition, comprising:(a) an active agent; and(b) a semi-solid delivery vehicle comprising:(i) a polyorthoester of formula I or formula II where:R is a bond, —(CH 2 ) a —, or —(CH 2 ) b —O—(CH 2 ) c —; where a is an integer of 1 to 10, and b and c are independently integers of 1 to 5;R* is a C 1-4 alkyl;n is an integer of at least 5; andA is R 1 , R 2 , R 3 , or R 4 , whereR 1 is: where:p is an integer of 1 to 20;R 5 is hydrogen or C 1-4 alkyl; andR 6 is: where:s is an integer of 0 to 30;t is an integer of 2 to 200; andR 7 is hydrogen or C 1-4 alkyl;R 2 is:R 3 is: where:x is an integer of 0 to 30;y is an integer of 2 to 200;R 8 is hydrogen or C 1-4 alkyl;R 9 and R 10 are independently C 1-12 alkylene;R 11 is hydrogen or C 1-6 alkyl and R 12 is C 1-6 alkyl; or R 11 and R 12 together are C 3-10 alkylene; andR 4 is a diol containing at least one functional group independently selected from amide, imide, urea, and urethane groups; in which at least 0.1 mol percent of the A units are of the formula R 1 , and(ii) a pharmaceutically acceptable, polyorthoester-compatible liquid excipient selected from polyethylene glycol ether derivatives having a molecular weight between 200 and 4000, polyethylene glycol copolymers having a molecular weight between 400 and 4000, mono-, di-, or tri-glycerides of a C 2-19 aliphatic carboxylic acid or a mixture of such acids, alkoxylated tetrahydrofurfuryl alcohols and their C 1-4 alkyl ethers and C 2-19 aliphatic carboxylic acid esters, and biocompatible oils. 2. The composition of claim 1 where the concentration of the polyorthoester ranges from 1% to 99% by weight of the delivery vehicle. 3. The composition of claim 1 where the polyorthoester has a molecular weight between 1000 and 20,000. 4. The composition of claim 1 where the fraction of the A units that are of the formula R 1 is between 1 and 90 mol percent. 5. The composition of claim 1 where the polyorthoester is of formula I, where:none of the units have A equal to R 2 ;R 3 is: where:x is an integer of 0 to 10;y is an integer of 2 to 30; andR 6 is: where:s is an integer of 0 to 10;t is an integer of 2 to 30; andR 5 , R 7 , and R 8 are independently hydrogen or methyl. 6. The composition of claim 5 where:R 3 and R 6 are both —(CH 2 —CH 2 —O) 2 —(CH 2 —CH 2 )—;R 5 is methyl; andp is 1 or 2. 7. The composition of claim 5 where:R 3 and R 6 are both —(CH 2 —CH 2 —O) 9 —(CH 2 —CH 2 )—;R 5 is methyl; andp is 1 or 2. 8. The composition of claim 1 where the fraction of the active agent is from 1% to 60% by weight of the composition. 9. The composition of claim 8 where the fraction of the active agent is from 5% to 30% by weight of the composition. 10. The composition of claim 1 where the composition is in topical, syringable, or injectable form. 11. The composition of claim 1 where the active agent is selected from anti-infectives, antiseptics, steroids, therapeutic polypeptides, anti-inflammatory agents, cancer chemotherapeutic agents, narcotics, local anesthetics, antiangiogenic agents, vaccines, antigens, DNA, and antisense oligonucleotides. 12. The composition of claim 11 where the active agent is a therapeutic polypeptide. 13. The composition of claim 12 where the active agent is bone morphogenic protein. 14. The composition of claim 11 where the active agent is a local anesthetic. 15. The composition of claim 14 further comprising a glucocorticosteroid. 16. The composition of claim 11 where the active agent is an antiangiogenic agent. 17. The composition of claim 11 where the active agent is a cancer chemotherapeutic agent. 18. The composition of claim 11 where the active agent is an antibiotic. 19. The composition of claim 11 where the active agent is an anti-inflammatory agent. 20. A method o f treating a disease state treatable by controlled release local administration of an active agent, comprising locally administering a therapeutically effective amount of the active agent in the form of a pharmaceutical composition of claim 1. 21. The method of claim 20 where the active agent is selected from anti-infectives, antiseptics, steroids, therapeutic polypeptides, anti-inflammatory agents, cancer chemotherapeutic agents, narcotics, local anesthetics, antiangiogenic agents, vaccines, antigens, DNA, and antisense oligonucleotides. 22. A method of preventing or relieving local pain at a site in a mammal, comprising administering to the site a therapeutically effective amount of a local anesthetic in the form of a pharmaceutically acceptable composition of claim 14. 23. A method of preventing or relieving local pain at a site in a mammal, comprising administering to the site a therapeutically effective amount of a local anesthetic in the form of a pharmaceutically acceptable composition of claim 15. 24. A process for the preparation of the pharmaceutical composition of claim 1 where the active agent is in solid form, comprising:(1) optionally milling the active agent to reduce the particle size of the active agent;(2) mixing the active agent and the delivery vehicle; and(3) optionally milling the composition to reduce the particle size of the active agent.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (24)
Shih Chung ; Zentner Gaylen M. ; Sparer Randall V. ; Seward R. Lee, Bioerodible implants.
Chandrashekar Bhagya L. ; Zhou Mingxing ; Jarr Eileen M. ; Dunn Richard L., Controlled release liquid delivery compositions with low initial drug burst.
Domb Abraham J.,ILX ; Gref Ruxandra,FRX ; Minamitake Yoshiharu,JPX ; Peracchia Maria Teresa,ITX ; Langer Robert S., Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers.
Heller Jorge (Woodside CA) Ng Steve Y. W. (San Francisco CA) Penhale Donald W. H. (Menlo Park CA), Polymers containing carboxy-ortho ester and ortho ester linkages.
Heller Jorge (Palo Alto CA) Helwing Robert F. (Sunnyvale CA) Penhale Donald W. (Cupertino CA), Polymers of di- (and higher functionality) ketene acetals and polyols.
Cohen Edward M. (Beaumont PA FRX) Grim Wayne M. (Doylestown PA) Harwood Richard J. (Philadelphia PA) Mehta Gunvant N. (Lansdale PA), Solid state ophthalmic medication.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.